GLP-1 Compounding Pharmacy Says Lilly, Novo Nordisk Violated Antitrust Laws
SAN ANTONIO — Manufacturers of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications approved by the U.S. Food and Drug Administration violated antitrust laws by unlawfully monopolizing the market and by entering...To view the full article, register now.
Already a subscriber? Click here to view full article